Vous êtes ici

2015

Ayrignac X, Carra-Dalliere C, Menjot de Champfleur N, Denier C, Aubourg P, Bellesme C, Castelnovo G, Pelletier J, Audoin B, Kaphan E, de Seze J, Collongues N, Blanc F, Chanson JB, Magnin E, Berger E, Vukusic S, Durand-Dubief F, Camdessanche JP, Cohen M, Lebrun-Frenay C, Brassat D, Clanet M, Vermersch P, Zephir H, Outteryck O, Wiertlewski S, Laplaud DA, Ouallet JC, Brochet B, Goizet C, Debouverie M, Pittion S, Edan G, Deburghgraeve V, Le Page E, Verny C, Amati-Bonneau P, Bonneau D, Hannequin D, Guyant-Maréchal L, Derache N, Defer GL, Moreau T, Giroud M, Guennoc AM, Clavelou P, Taithe F, Mathis S, Neau JP, Magy L, Devoize JL, Bataillard M, Masliah-Planchon J, Dorboz I, Tournier-Lasserve E, Levade T, Boespflug Tanguy O, Labauge P. Adult-onset genetic leukoencephalopathies: a MRI pattern-based approach in a comprehensive study of 154 patients. Brain. 2015;138(Pt 2):284-92. IF2015 = 10.103; 5YIF = 10.545

 

Sepulveda-Diaz JE, Alavi Naini SM, Huynh MB, Ouidja MO, Yanicostas C, Chantepie S, Villares J, Lamari F, Jospin E, van Kuppevelt TH, Mensah-Nyagan AG, Raisman-Vozari R, Soussi-Yanicostas N, Papy-Garcia D. HS3ST2 expression is critical for the abnormal phosphorylation of tau in Alzheimer's disease-related tau pathology. Brain. 2015;138(Pt 5):1339-54. IF2015 = 10.103; 5YIF = 10.545

 

Kremer S, Renard F, Achard S, Lana-Peixoto MA, Palace J, Asgari N, Klawiter EC, Tenembaum SN, Banwell B, Greenberg BM, Bennett JL, Levy M, Villoslada P, Saiz A, Fujihara K, Chan KH, Schippling S, Paul F, Kim HJ, de Seze J, Wuerfel JT, Guthy-Jackson Charitable Foundation (GJCF) Neuromyelitis Optica (NMO) International Clinical Consortium and Biorepository, Cabre P, Marignier R, Tedder T, van Pelt D, Broadley S, Chitnis T, Wingerchuk D, Pandit L, Leite MI, Apiwattanakul M, Kleiter I, Prayoonwiwat N, Han M, Hellwig K, van Herle K, John G, Hooper DC, Nakashima I, Sato D, Yeaman MR, Waubant E, Zamvil S, Stüve O, Aktas O, Smith TJ, Jacob A, O'Connor K. Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. JAMA Neurol. 2015;72(7):815-22. IF2015 = 8.230; 5YIF = 8.236

 

Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG, International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;14;85(2):177-89. IF2015 = 8.166; 5YIF = 8.092

 

Weinshenker BG, Barron G, Behne JM, Bennett JL, Chin PS, Cree BA, de Seze J, Flor A, Fujihara K, Greenberg B, Higashi S, Holt W, Khan O, Knappertz V, Levy M, Melia AT, Palace J, Smith TJ, Sormani MP, Van Herle K, VanMeter S, Villoslada P, Walton MK, Wasiewski W, Wingerchuk DM, Yeaman MR, Guthy-Jackson Charitable Foundation International Clinical Consortium. Challenges and opportunities in designing clinical trials for neuromyelitis optica. Neurology. 2015;84(17):1805-15. IF2015 = 8.166; 5YIF = 8.092

 

Miller DH, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Kita M, Wheeler-Kingshott CA, Tozer DJ, MacManus DG, Yousry TA, Goodsell M, Yang M, Zhang R, Viglietta V, Dawson KT, CONFIRM study investigators. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology. 2015;84(11):1145-52. IF2015 = 8.166; 5YIF = 8.092

 

Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, Klawiter EC, Sato DK, de Seze J, Wuerfel J, Banwell BL, Villoslada P, Saiz A, Fujihara K, Kim SH, Guthy-Jackson Charitable Foundation NMO International Clinical Consortium & Biorepository. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015;84(11):1165-73. IF2015 = 8.166; 5YIF = 8.092

 

Pröbstel AK, Rudolf G, Dornmair K, Collongues N, Chanson JB, Sanderson NS, Lindberg RL, Kappos L, de Seze J, Derfuss T. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflammation. 2015;12:46. IF2015 = 4.667; 5YIF = 5.366

 

Klein C, Mathis C, Leva G, Patte-Mensah C, Cassel JC, Maitre M, Mensah-Nyagan AG. γ-Hydroxybutyrate (Xyrem) ameliorates clinical symptoms and neuropathology in a mouse model of Alzheimer's disease. Neurobiol Aging. 2015;36(2):832-44. IF2015 = 5.153; 5YIF = 5.193

 

Heitz C, Noblet V, Cretin B, Philippi N, Kremer L, Stackfleth M, Hubele F, Armspach JP, Namer I, Blanc F. Neural correlates of visual hallucinations in dementia with Lewy bodies. Alzheimers Res Ther. 2015;7(1):6. IF2015 = 5.197; 5YIF = 5.126

 

Baron W, Ozgen H, Klunder B, de Jonge JC, Nomden A, Plat A, Trifilieff E, de Vries H, Hoekstra D. The major myelin-resident protein PLP is transported to myelin membranes via a transcytotic mechanism: involvement of sulfatide. Mol Cell Biol. 2015;35(1):288-302. IF2015 = 4.427; 5YIF = 4.782

 

Bennett JL, de Seze J, Lana-Peixoto M, Palace J, Waldman A, Schippling S, Tenembaum S, Banwell B, Greenberg B, Levy M, Fujihara K, Chan KH, Kim HJ, Asgari N, Sato DK, Saiz A, Wuerfel J, Zimmermann H, Green A, Villoslada P, Paul F, GJCF-ICC&BR. Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. Mult Scler. 2015;21(6):678-88. IF2015 = 4.671; 5YIF = 4.546

 

Kemmel V, Mercoli HA, Meyer N, Brumaru D, Romain B, Lessinger JM, Brigand C. Mitomycin C Pharmacokinetics as Predictor of Severe Neutropenia in Hyperthermic Intraperitoneal Therapy. Ann Surg Oncol. 2015;22 Suppl 3:S873-9. IF2015 = 3.655; 5YIF = 4.239

 

Leray E, Vukusic S, Debouverie M, Clanet M, Brochet B, de Seze J, Zéphir H, Defer G, Lebrun-Frenay C, Moreau T, Clavelou P, Pelletier J, Berger E, Cabre P, Camdessanché JP, Kalson-Ray S, Confavreux C, Edan G. Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study. PLoS One. 2015;10(7):e0132033. IF2015 = 3.057; 5YIF = 3.535

 

Henriques A, Blasco H, Fleury MC, Corcia P, Echaniz-Laguna A, Robelin L, Rudolf G, Lequeu T, Bergaentzle M, Gachet C, Pradat PF, Marchioni E, Andres CR, Tranchant C, Gonzalez De Aguilar JL, Loeffler JP. Blood Cell Palmitoleate-Palmitate Ratio Is an Independent Prognostic Factor for Amyotrophic Lateral Sclerosis. PLoS One. 2015;10(7):e0131512. IF2015 = 3.057; 5YIF = 3.535

 

Pape E, Scala-Bertola J, Petitpain N, Jouzeau JY, Charrois-Sciaudeau S, Kemmel V, Barraud H, Gambier N. Management of Tacrolimus-Telaprevir Drug-Drug Interaction in a Liver Transplant Patient With Hepatitis C Virus: Practical Considerations. Transplantation. 2015;99(9):e163-4. IF2015 = 3.690; 5YIF = 3.446

 

Charlier TD, Cornil CA, Patte-Mensah C, Meyer L, Mensah-Nyagan AG, Balthazart J. Local modulation of steroid action: rapid control of enzymatic activity. Front Neurosci. 2015;9:83. IF2015 = 3.398

 

Siri A, Carra-Dalliere C, Ayrignac X, Pelletier J, Audoin B, Pittion-Vouyovitch S, Debouverie M, Lionnet C, Viala F, Sablot D, Brassat D, Ouallet JC, Ruet A, Brochet B, Taillandier L, Bauchet L, Derache N, Defer G, Cabre P, de Seze J, Lebrun Frenay C, Cohen M, Labauge P. Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study. J Neurol. 2015;262(7):1637-45. IF2015 = 3.408; 5YIF = 3.349

 

Chanson JB, Boehm N, Samama B, Echaniz-Laguna A, Anheim M. Small fiber neuropathy in a woman with fragile X-associated tremor/ataxia syndrome (FXTAS). J Neurol. 2015;262(1):226-7. IF2015 = 3.408; 5YIF = 3.349

 

Renaud M, Perriard J, Coudray S, Sévin-Allouet M, Marcel C, Meissner WG, Chanson JB, Collongues N, Philippi N, Gebus O, Quenardelle V, Castrioto A, Krack P, N'Guyen K, Lefebvre F, Echaniz-Laguna A, Azulay JP, Meyer N, Labauge P, Tranchant C, Anheim M. Relevance of corpus callosum splenium versus middle cerebellar peduncle hyperintensity for FXTAS diagnosis in clinical practice. J Neurol. 2015;262(2):435-42. IF2015 = 3.408; 5YIF = 3.349

 

Kaufman M, Cree BA, De Seze J, Fox RJ, Gold R, Hartung HP, Jeffery D, Kappos L, Montalbán X, Weinstock-Guttman B, Ticho B, Duda P, Pace A, Campagnolo D. Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. J Neurol. 2015;262(2):326-36. IF2015 = 3.408; 5YIF = 3.349

 

Béreau M, Anheim M, Chanson JB, Tio G, Echaniz-Laguna A, Depienne C, Collongues N, de Seze J. Dalfampridine in hereditary spastic paraplegia: a prospective, open study. J Neurol. 2015;262(5):1285-8. IF2015 = 3.408; 5YIF = 3.349

 

Ernst A, Blanc F, De Seze J, Manning L. Using mental visual imagery to improve autobiographical memory and episodic future thinking in relapsing-remitting multiple sclerosis patients: A randomised-controlled trial study. Restor Neurol Neurosci. 2015;33(5):621-38. IF2015 = 2.661; 5YIF = 3.205

 

Brun S, Beaino W, Kremer L, Taleb O, Mensah-Nyagan AG, Lam CD, Greer JM, de Seze J, Trifilieff E. Characterization of a new rat model for chronic inflammatory demyelinating polyneuropathies. J Neuroimmunol. 2015;278:1-10. IF2015 = 2.536; 5YIF = 2.670

 

Ernst A, Noblet V, Gounot D, Blanc F, de Seze J, Manning L. Neural correlates of episodic future thinking impairment in multiple sclerosis patients. J Clin Exp Neuropsychol. 2015;37(10):1107-23. IF2015 = 1.693; 5YIF = 2.325

 

Ernst A, Noblet V, Denkova E, Blanc F, de Seze J, Gounot D, Manning L. Functional cerebral changes in multiple sclerosis patients during an autobiographical memory test. Memory. 2015;23(8):1123-39. IF2015 = 1.976; 5YIF = 2.069

 

 

Cotton F, Kremer S, Hannoun S, Vukusic S, Dousset V; Imaging Working Group of the Observatoire Français de la Sclérose en Plaques. OFSEP, a nationwide cohort of people with multiple sclerosis: Consensus minimal MRI protocol. J Neuroradiol. 2015;42(3):133-40. IF2015 =2.759; 5YIF = 1.780

 

Ongagna JC, Passadori A, Pinelli J, Isner-Horobeti ME, Zaenker C, De Seze J. [Difficulties experienced at work by patients with multiple sclerosis]. Rev Neurol (Paris). 2015;171(11):782-6. IF2015 = 0.955; 5YIF = 0.711

 

Lairy G, Zephir H, Ouallet JC, Le Page E, Laplaud D, Bensa C, De Seze J. Targeted clinical audits immediately following the establishment of clinical practice guidelines for multiple sclerosis in 17 neurology departments: A pragmatic and collaborative study. Rev Neurol (Paris). 2015;171(5):407-14. IF2015 = 0.955; 5YIF = 0.711

 

Felten R, Benoilid A, Alves Do Rego C, Collongues N, De Seze J. [Unilateral mydriasis in Lyme neuroborreliosis]. Rev Neurol (Paris). 2015;171(5):451-2. IF2015 = 0.955; 5YIF = 0.711

 

Lebrun C, Forzy G, Collongues N, Cohen M, de Seze J, Hautecoeur P, Club francophone de la SEP and RISConsortium. Tear analysis as a tool to detect oligoclonal bands in radiologically isolated syndrome. Rev Neurol (Paris). 2015;171(4):390-3. IF2015 = 0.955; 5YIF = 0.711

 

Melamed E, Levy M, Waters PJ, Sato DK, Bennett JL, John GR, Hooper DC, Saiz A, Bar-Or A, Kim HJ, Pandit L, Leite MI, Asgari N, Kissani N, Hintzen R, Marignier R, Jarius S, Marcelletti J, Smith TJ, Yeaman MR, Han MH, Aktas O, Apiwattanakul M, Banwell B, Bichuetti D, Broadley S, Cabre P, Chitnis T, De Seze J, Fujihara K, Greenberg B, Hellwig K, Iorio R, Jarius S, Klawiter E, Kleiter I, Lana-Peixoto M, Nakashima, O'Connor K, Palace J, Paul F, Prayoonwiwat N, Ruprecht K, Stuve O, Tedder T, Tenembaum S, Garrahan JP, Aires B, van Herle K, van Pelt D, Villoslada P, Waubant E, Weinshenker B, Wingerchuk D, Würfel J, Zamvil S. Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015;2(4):e134.